@article{e318e7e0201c4d609b50397778ab4cd9,
title = "Biomarker use in lung cancer management: Expanding horizons",
keywords = "ALK, EGFR, biomarkers, ctDNA, immunotherapy, lung cancer, molecular testing, targeted therapy",
author = "Sandler, {Jason E.} and Meghan Kaumaya and Balazs Halmos",
note = "Funding Information: B Halmos has received research support from Merck, Mirati, Pfizer, Boehringer-Ingelheim, Eli-Lilly, Astra-Zeneca and consulting fees from Novartis, Foundation One, Guardant Health, Eli-Lilly, Pfizer, Novartis, Takeda, Boehringer-Ingelheim and Astra-Zeneca. J Sandler and M Kaumaya have no conflicts of interest to disclose. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.",
year = "2018",
month = apr,
doi = "10.2217/bmm-2018-0028",
language = "English (US)",
volume = "12",
pages = "315--320",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "4",
}
